What is the long-term trend for Veracyte's contingent consideration fair value adjustments?

Over 3 years (2021 to 2025), Veracyte's contingent consideration fair value adjustments has grown at a 167.2% compound annual growth rate (CAGR), from $810K to -$15.46M.

Veracyte VCYT Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Natera, Inc.NTRA

——

RevvityRVTY

——

Other financials

Income statement

See full

Revenue$139.1M+21.5%

Gross profit$101.2M+27.2%

Operating income$22.6M+680%

Net income$28.7M+307%

EPS (diluted)$0.35+289%

Balance sheet

See full

Cash & equivalents$264.8M+41.0%

Total debt$39.3M-22.1%

Total equity$1.3B+12.5%

Total assets$1.4B+9.2%

Cash flow

See full

Operating cash flow$35.2M+557%

CapEx$3.0M+62.8%

Free cash flow$32.3M+810%

Valuation

See full

Market cap$4.29B+10.7%

Profitability

See full

Gross margin70.9%+2.9pp

Operating margin14.3%+9.2pp

Net margin16.2%+9.1pp

FCF margin28.7%+11.7pp

Returns & leverage

See full

Return on equity6.9%+4.1pp

Debt / equity0×0.0×

Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Veracyte's contingent consideration fair value adjustments?: Veracyte (VCYT) reported contingent consideration fair value adjustments of -$350K in Q1 2026.
How has Veracyte's contingent consideration fair value adjustments changed year-over-year?: Veracyte's contingent consideration fair value adjustments increased by 82.1% year-over-year, from -$1.95M to -$350K.
What is the long-term trend for Veracyte's contingent consideration fair value adjustments?: Over 3 years (2021 to 2025), Veracyte's contingent consideration fair value adjustments has grown at a 167.2% compound annual growth rate (CAGR), from $810K to -$15.46M.